Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting

Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting In the poster, entitled “EGL-001 is a novel immunocytokine designed to specifically target and disarm T regulatory cells in the tumor microenvironment”. Egle scientists present evidence that EGL-001, a CTLA-4 targeted IL-2 dominant negative mutein, selectively […]
Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointments of Jeltje Schulten, M.D., MBA, as SVP of clinical and medical affairs and Rita Dalal, MBBS, MPH, as vice president of clinical development. “With our first-in-class EGFR/TGF-β-trap bifunctional antibody, BCA101, advancing in the clinic […]
Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever. PRTX007 is a clinical-stage novel oral small molecule that […]
Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO). Dan’s deep […]
Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing

Proceeds to accelerate clinical development of first-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, for multiple cancer types, including 1L HPV-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) Presented positive interim clinical data at 2023 ASCO Annual Meeting and ESMO Congress 2023 from ongoing Phase 1/1b dose expansion study of BCA101 in combination with pembrolizumab demonstrating […]
Bicara Therapeutics Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023

First-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, in combination with pembrolizumab continues to demonstrate clinically meaningful preliminary anti-tumor activity consistent with previous results Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the presentation of updated, positive interim data from its ongoing, open-label Phase 1/1b dose expansion […]
Bicara Therapeutics Expands Board of Directors with Appointments of Kate Haviland and Scott Robertson

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the expansion of its board of directors with the appointments of biopharmaceutical industry veterans Kate Haviland and Scott Robertson. “Kate and Scott bring an impressive breadth of experience and leadership within the biopharmaceutical industry, as well […]
Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, today announced the upcoming presentation of new clinical data from its Phase 1 study of PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the 2023 American Association for the Study of Liver Diseases (AASLD) […]
Anavo Therapeutics strengthens management team

Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of phosphatase biology, announced the appointment of Shaun McNulty, DPhil, as Chief Scientific Officer (CSO) and the appointment of Anna Quattropani, PhD, as Senior Vice President of Chemistry and Non-Clinical Development. Dr. McNulty will oversee the implementation of Anavo’s strategy from discovery into clinical […]
Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointment of David Raben, M.D., as chief medical officer. Dr. Raben joins Bicara with more than 25 years of biopharma and academic translational oncology experience, having most recently served as vice president of global product […]